269 related articles for article (PubMed ID: 21946274)
1. A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer.
Muellner MK; Uras IZ; Gapp BV; Kerzendorfer C; Smida M; Lechtermann H; Craig-Mueller N; Colinge J; Duernberger G; Nijman SM
Nat Chem Biol; 2011 Sep; 7(11):787-93. PubMed ID: 21946274
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells.
Yi YW; Kang HJ; Kim HJ; Hwang JS; Wang A; Bae I
Mol Carcinog; 2013 Sep; 52(9):667-75. PubMed ID: 22488590
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms of tumor resistance to PI3K-mTOR-targeted therapy.
Tan J; Yu Q
Chin J Cancer; 2013 Jul; 32(7):376-9. PubMed ID: 23668928
[TBL] [Abstract][Full Text] [Related]
4. PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition.
Brady SW; Zhang J; Tsai MH; Yu D
Cancer Biol Ther; 2015; 16(3):402-11. PubMed ID: 25692408
[TBL] [Abstract][Full Text] [Related]
5. Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT.
O'Brien NA; McDonald K; Tong L; von Euw E; Kalous O; Conklin D; Hurvitz SA; di Tomaso E; Schnell C; Linnartz R; Finn RS; Hirawat S; Slamon DJ
Clin Cancer Res; 2014 Jul; 20(13):3507-20. PubMed ID: 24879796
[TBL] [Abstract][Full Text] [Related]
6. Targeting PI3K in cancer: mechanisms and advances in clinical trials.
Yang J; Nie J; Ma X; Wei Y; Peng Y; Wei X
Mol Cancer; 2019 Feb; 18(1):26. PubMed ID: 30782187
[TBL] [Abstract][Full Text] [Related]
7. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
[TBL] [Abstract][Full Text] [Related]
8. A molecular sub-cluster of colon cancer cells with low VDR expression is sensitive to chemotherapy, BRAF inhibitors and PI3K-mTOR inhibitors treatment.
Wang H; Wang X; Xu L; Zhang J; Cao H
Aging (Albany NY); 2019 Oct; 11(19):8587-8603. PubMed ID: 31596728
[TBL] [Abstract][Full Text] [Related]
9. Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.
Sheppard KE; Cullinane C; Hannan KM; Wall M; Chan J; Barber F; Foo J; Cameron D; Neilsen A; Ng P; Ellul J; Kleinschmidt M; Kinross KM; Bowtell DD; Christensen JG; Hicks RJ; Johnstone RW; McArthur GA; Hannan RD; Phillips WA; Pearson RB
Eur J Cancer; 2013 Dec; 49(18):3936-44. PubMed ID: 24011934
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of mTOR signaling reduces PELP1-mediated tumor growth and therapy resistance.
Gonugunta VK; Sareddy GR; Krishnan SR; Cortez V; Roy SS; Tekmal RR; Vadlamudi RK
Mol Cancer Ther; 2014 Jun; 13(6):1578-88. PubMed ID: 24688046
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory role of large intergenic noncoding RNA-ROR on tamoxifen resistance in the endocrine therapy of breast cancer by regulating the PI3K/Akt/mTOR signaling pathway.
Lu PW; Li L; Wang F; Gu YT
J Cell Physiol; 2019 Feb; 234(2):1904-1912. PubMed ID: 30145819
[TBL] [Abstract][Full Text] [Related]
12. PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response.
Shepherd C; Banerjee L; Cheung CW; Mansour MR; Jenkinson S; Gale RE; Khwaja A
Leukemia; 2013 Mar; 27(3):650-60. PubMed ID: 23038273
[TBL] [Abstract][Full Text] [Related]
13. G0S2 represses PI3K/mTOR signaling and increases sensitivity to PI3K/mTOR pathway inhibitors in breast cancer.
Yim CY; Bikorimana E; Khan E; Warzecha JM; Shin L; Rodriguez J; Dmitrovsky E; Freemantle SJ; Spinella MJ
Cell Cycle; 2017; 16(21):2146-2155. PubMed ID: 28910567
[TBL] [Abstract][Full Text] [Related]
14. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C
Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343
[TBL] [Abstract][Full Text] [Related]
15. Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.
Kampa-Schittenhelm KM; Heinrich MC; Akmut F; Rasp KH; Illing B; Döhner H; Döhner K; Schittenhelm MM
Mol Cancer; 2013 May; 12():46. PubMed ID: 23705826
[TBL] [Abstract][Full Text] [Related]
16. AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.
Ribas R; Pancholi S; Guest SK; Marangoni E; Gao Q; Thuleau A; Simigdala N; Polanska UM; Campbell H; Rani A; Liccardi G; Johnston S; Davies BR; Dowsett M; Martin LA
Mol Cancer Ther; 2015 Sep; 14(9):2035-48. PubMed ID: 26116361
[TBL] [Abstract][Full Text] [Related]
17. Oxidative stress downstream of mTORC1 but not AKT causes a proliferative defect in cancer cells resistant to PI3K inhibition.
Dermit M; Casado P; Rajeeve V; Wilkes EH; Foxler DE; Campbell H; Critchlow S; Sharp TV; Gribben JG; Unwin R; Cutillas PR
Oncogene; 2017 May; 36(19):2762-2774. PubMed ID: 27991931
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of DNA methyltransferase as a novel therapeutic strategy to overcome acquired resistance to dual PI3K/mTOR inhibitors.
Qian XJ; Li YT; Yu Y; Yang F; Deng R; Ji J; Jiao L; Li X; Wu RY; Chen WD; Feng GK; Zhu XF
Oncotarget; 2015 Mar; 6(7):5134-46. PubMed ID: 25762617
[TBL] [Abstract][Full Text] [Related]
19. Somatic loss of PIK3R1 may sensitize breast cancer to inhibitors of the MAPK pathway.
Turturro SB; Najor MS; Yung T; Portt L; Malarkey CS; Abukhdeir AM; Cobleigh MA
Breast Cancer Res Treat; 2019 Sep; 177(2):325-333. PubMed ID: 31209687
[TBL] [Abstract][Full Text] [Related]
20. Suppression of PI3K/Akt/mTOR/c-Myc/mtp53 Positive Feedback Loop Induces Cell Cycle Arrest by Dual PI3K/mTOR Inhibitor PQR309 in Endometrial Cancer Cell Lines.
Hsin IL; Shen HP; Chang HY; Ko JL; Wang PH
Cells; 2021 Oct; 10(11):. PubMed ID: 34831139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
